Pharma Now: FDA and Reagan-Udall Foundation Convene August 2026 Meeting to Advance Drug Repurposing Selection Criteria

Manufacturing capacity already validated under 21 CFR Part 211 and existing safety dossiers could become strategic assets as the Reagan-Udall Foundation for the FDA convenes a hybrid public meeting on August 5, 2026, to shape how repurposing candidates for approved drugs are selected and prioritized.